Loading...
XSWXBSLN
Market cap555mUSD
Dec 23, Last price  
41.15CHF
1D
-0.48%
1Q
-10.83%
Jan 2017
-43.71%
Name

Basilea Pharmaceutica AG Allschwil

Chart & Performance

D1W1MN
XSWX:BSLN chart
P/E
47.73
P/S
3.16
EPS
0.86
Div Yield, %
0.00%
Shrs. gr., 5y
2.30%
Rev. gr., 5y
3.53%
Revenues
158m
+6.68%
286,70430,494,9207,183,7807,898,45011,974,20826,828,225115,555,21466,149,58958,335,75240,950,66842,499,00052,825,00065,983,999101,521,000132,555,000134,381,000127,629,000148,122,000147,765,000157,634,000
Net income
10m
-13.96%
-75,472,043-49,595,730-85,149,690-126,819,540-143,528,034-120,736,494107,564,085-57,645,627-53,033,105-33,019,931-41,546,000-61,603,000-51,287,000-19,360,000-31,352,000-22,422,000-14,722,000-6,831,00012,147,00010,451,000
CFO
14m
+101.88%
-64,203,93034,380,170-72,465,080-78,987,770-127,165,900-114,510,110106,635,957-82,376,566148,174,455-59,469,815-71,461,000-67,780,000-75,003,00019,014,000-79,210,000-63,836,000-54,134,000-32,020,0007,056,00014,245,000
Dividend
Apr 11, 20135 CHF/sh
Earnings
Feb 11, 2025

Profile

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
URL
https://www.basilea.com/
IPO date
Mar 25, 2004
Employees
143
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
157,634
6.68%
147,765
-0.24%
148,122
16.06%
Cost of revenue
138,429
162,237
176,671
Unusual Expense (Income)
NOPBT
19,205
(14,472)
(28,549)
NOPBT Margin
12.18%
Operating Taxes
10
(45)
37
Tax Rate
0.05%
NOPAT
19,195
(14,427)
(28,586)
Net income
10,451
-13.96%
12,147
-277.82%
(6,831)
-53.60%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,009
4,426
39,852
BB yield
-0.47%
-0.81%
-8.34%
Debt
Debt current
17,515
39,455
124,401
Long-term debt
128,789
147,683
94,554
Deferred revenue
9,460
10,693
11,926
Other long-term liabilities
15,149
8,337
24,986
Net debt
86,404
77,305
66,612
Cash flow
Cash from operating activities
14,245
7,056
(32,020)
CAPEX
(813)
(3,303)
(860)
Cash from investing activities
(1,034)
91,649
3,575
Cash from financing activities
(57,305)
(45,246)
16,640
FCF
11,448
(45,371)
(59,500)
Balance
Cash
59,900
86,567
149,953
Long term investments
23,266
2,390
Excess cash
52,018
102,445
144,937
Stockholders' equity
(997,997)
(1,001,764)
(1,031,844)
Invested Capital
1,141,209
1,169,894
1,227,594
ROIC
1.66%
ROCE
13.41%
EV
Common stock shares outstanding
12,143
11,944
11,682
Price
35.30
-22.93%
45.80
11.93%
40.92
-23.01%
Market cap
428,651
-21.64%
547,013
14.43%
478,026
-12.52%
EV
515,055
624,318
544,638
EBITDA
22,682
(11,375)
(26,095)
EV/EBITDA
22.71
Interest
11,202
11,011
11,063
Interest/NOPBT
58.33%